Semaglutide vs Canagliflozin for Type 2 Diabetes

About this episode

This episode discusses a study comparing semaglutide and canagliflozin in the treatment of Type 2 Diabetes.

In this episode of Hormone Insight, we delve into a major study published in The Lancet Diabetes and Endocrinology that compared the effects of semaglutide and canagliflozin as add-ons to metformin in diabetes treatment. For more: Semaglutide vs Canagliflozin for Type 2 Diabetes To read the original paper

People in this episode

Host: FWA

Topics covered

• diabetes treatment
• semaglutide
• canagliflozin
• metformin
• clinical study
• endocrinology

Keywords

• semaglutide
• canagliflozin
• Type 2 Diabetes
• metformin
• diabetes treatment
• clinical study

Mentioned in this episode

Organizations: The Lancet Diabetes and Endocrinology

Products: semaglutide, canagliflozin, metformin

Places: Type 2 Diabetes

More episodes of Hormone Insight

• The Week in Endocrinology Oral Ozempic & Emerging Therapies · May 12, 2026 · 5 min
• Week in Diabetes & Endocrinology (May 4, 2026): AID in Pregnancy, Tirzepatide ICERs, AACE Signals, Dapagliflozin & Anemia, Hypoglycemia Models, Oat Diet Trial · May 5, 2026 · 16 min
• HORMONE INSIGHT -- THE WEEK IN DIABETES & ENDOCRINOLOGY -- Episode 004 | April 24, 2026 · April 24, 2026 · 14 min
• The Week in Diabetes and Endocrinology April 17, 2026 · April 22, 2026 · 18 min
• Episode 002: LDL Under 55 Wins Big, Medicare Covers GLP-1, and Second Weekly Insulin Emerges -- The Week in Diabetes & Endocrinology (April 10, 2026) · April 9, 2026 · 17 min
• The Week in Diabetes and Endocrinology -- April 3, 2026 · April 5, 2026 · 24 min